Loading
Tactile Systems Technology Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 08 Aug 2022.
Tactile Systems Technology Inc: what insiders have been doing
Tactile Systems Technology Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Tactile Systems Technology Inc logged 13 filings by 6 insiders.
Only sales appear on the open market, 4 sales in all totalling €738k, filed by 3 insiders. Dodd Sheri Louise filed the largest sale, €270k, on 26 February 2026.
Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,816 companies, median 19 filings), a count of 13 filings is below the norm. Our records for Tactile Systems Technology Inc go back to 2021, with 1 purchase and 32 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 329.5 m USD and net income at 19.1 m USD.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
108
Thresholds
n/a
Buy Volume
€43,751
1 ops. · all time
Sell Volume
€2M
32 ops. · all time
Who traded when
BuySaleDodd Sheri Louise4 sales
Elaine M. Birkemeyer3 sales
Kristie Burns3 sales
Daniel L. Reuvers1 sale
Since the insiders bought
- +93.4%Entry US$9.40 · Close at T+365 US$18.18
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Tactile Systems Technology Inc Strong Buy (bullish), based on 3 analysts. Average price target: US$37.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 5,378 of 24,158 companies
65.6
score / 100
Value58
Quality73
FCF yld7.9%
Earn yld3.7%
EV/EBITDA13.5x
ROE12%
Gross mgn76%
Net mgn5.8%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$22.41
Analyst consensus
3 analystsStrong buy
US$35.00Target US$37.67(+68%)US$40.00
Income statement
RevenueUS$329.5M
Gross profitUS$250.1M76% margin
EBITDAUS$39M12% margin
Net incomeUS$19.1M7.1% margin
Valuation
PER (trailing)20.7x
PER (forward)15.4x
P/Book2.3x
Beta0.82
Balance sheet & cash
Market capUS$507.6M
Total debtUS$16M
Free Cash FlowUS$40.3M
Debt / Equity6%
Profitability & ownership
ROE11.9%
ROA7.9%
% insiders2.3%
% institutions106.0%
Last declaration on 20 August 2026
Declarations108 total
15,000 shares@ €31,100.9672CommonSEC144:0001628280-26-058210
10,978 shares@ US$29.44460.063% mcap42.4% of flowCommonSEC144:0001959173-26-005855
852 shares0Common StockSEC:0001478345-26-000008:0
7,701 shares@ US$28.941767.0% of flowCommon StockSEC:0001968559-26-000005:0
6,246 shares@ US$28.940833.9% of flowCommon StockSEC:0001857721-26-000007:0
10,993 shares@ US$28.940640.9% of flowCommon StockSEC:0001837111-26-000005:0
3,579 shares0Common StockSEC:0001968559-26-000004:0
3,490 shares0Common StockSEC:0001857721-26-000006:0
19,751 shares0Common StockSEC:0001837111-26-000004:0
48,672 shares0Common StockSEC:0001837111-26-000002:0
23,008 shares0Common StockSEC:0001968559-26-000002:0
6,194 shares0Common StockSEC:0001857721-26-000004:0
5,139 shares@ US$28.8527.9% of flowCommon StockSEC:0001857721-26-000002:0
7,762 shares@ US$12.35612.5% of flowCommon StockSEC:0001415889-25-021513:0
2,921 shares@ US$9.94099.3% of flowCommon StockSEC:0001437749-25-016924:0
3,149 shares@ US$9.834.2% of flowCommon StockSEC:0001437749-25-016138:0
16,078 shares0Common StockSEC:0001437749-25-015798:0
16,078 shares0Common StockSEC:0001437749-25-015795:0
16,078 shares0Common StockSEC:0001437749-25-015802:0
16,078 shares0Common StockSEC:0001437749-25-015796:0
16,078 shares0Common StockSEC:0001437749-25-015800:0
16,078 shares0Common StockSEC:0001437749-25-015801:0
16,078 shares0Common StockSEC:0001437749-25-015794:0
68,162 shares0Common StockSEC:0001437749-25-007530:0
6,468 shares@ US$14.403219.7% of flowCommon StockSEC:0001437749-25-005484:0
25 of 108 declarations
About Tactile Systems Technology Inc
Tactile Systems Technology, Inc. is a U.S.-based medical technology company listed on the Nasdaq under the ticker TCMD in the United States. The company develops and commercializes at-home medical devices for underserved chronic conditions, with a strategy centered on reimbursement-supported therapies, clinician referrals, and direct patient engagement. Originally incorporated in Minnesota in 1995, the company later reincorporated in Delaware and operates today from its headquarters in Minneapolis, Minnesota. It began doing business as “Tactile Medical” in 2013. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1027838/000155837025001096/tcmd-20241231x10k.htm))
Tactile Medical’s core business is organized around two main therapeutic franchises. The first is pneumatic compression therapy for lymphedema and chronic venous insufficiency, marketed through the Flexitouch Plus, Entre Plus, and Nimbl systems. The second is airway clearance therapy, led by AffloVest, a portable high-frequency chest wall oscillation vest used for certain chronic respiratory disorders. In practical terms, the company sits at the intersection of medtech, chronic disease management, and home-based care. Its products are designed to be used outside the hospital, which is a meaningful differentiator in an environment where payers and policymakers increasingly favor lower-cost, home-delivered treatment pathways. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1027838/000155837025001096/tcmd-20241231x10k.htm))
Read moreShow less
From a competitive standpoint, Tactile Medical emphasizes clinically differentiated, proprietary devices rather than commodity hardware. Flexitouch Plus is its advanced programmable platform, designed for multiple body areas and supported by Bluetooth-enabled data reporting through the Kylee companion app. Entre Plus addresses patients who need a simpler pump or who have not yet qualified for advanced-device reimbursement. Nimbl is the next-generation platform, cleared by the FDA in 2024 and commercially available in the United States, with broader launch activity in 2025. The company also notes that its in-network or contracted payer coverage extends across more than 275 million lives in the United States, underscoring the importance of reimbursement access in its commercial model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1027838/000155837025001096/tcmd-20241231x10k.htm))
Geographically, the business is overwhelmingly U.S.-centric. Revenue is derived primarily from sales and rentals to patients in the United States, as well as sales to durable medical equipment providers for AffloVest. The company uses a direct-to-patient and direct-to-provider model for its lymphedema portfolio, while respiratory products are distributed through DME channels. This creates a hybrid go-to-market structure that combines clinical education, insurance processing, and patient onboarding. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1027838/000155837025001096/tcmd-20241231x10k.htm))
Recent developments have been constructive. In February 2025, Tactile Medical expanded the commercial launch of Nimbl to include lower-extremity lymphedema patients in the U.S. In its February 2026 full-year earnings release, the company reported 2025 revenue growth of 12% year over year and highlighted improved gross margin and profitability metrics. It also announced a second share repurchase program in late 2025, indicating greater capital return discipline. For investors, TCMD remains a niche U.S. medtech story with exposure to reimbursement trends, product adoption, and execution on newer platforms. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/02/04/3020263/0/en/Tactile-Medical-Expands-Launch-of-Nimbl-to-Include-Patients-with-Lower-Extremity-Lymphedema.html))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
